Aldeyra Therapeutics (ALDX) Announces Clinically Meaningful Data from Sermatologic NS2 Study in SLS
- AT&T (T) Agrees to Acquire Time Warner (TWX) for More than $80 Billion - WSJ
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) reported positive data from a randomized, parallel-group, double-blind, vehicle-controlled, multi-center clinical trial of topical dermatologic NS2, a novel aldehyde trap, for the treatment of the dermal manifestations of Sjögren-Larsson Syndrome (SLS).
"The results of this randomized and controlled clinical trial represent a significant advance in the effort to develop a treatment for SLS," said Dr. William Rizzo, the principal investigator of the trial and a leading expert in SLS. "The data from this trial suggest that NS2, when applied topically to the skin, has the potential to help patients suffering from SLS by lowering toxic aldehyde levels and preventing the dermal dysfunction that causes ichthyosis. I am excited about these results, and I am particularly excited for SLS patients and their caregivers."
Patients with SLS, a rare inborn error of aldehyde metabolism, suffer from ichthyosis, a debilitating dermatologic disease characterized by dry, thickened, scaly skin. The symptoms of SLS are thought to be related to high levels of toxic fatty aldehydes due to genetic mutations in fatty aldehyde dehydrogenase, an enzyme critical for the normal function of skin and other organs. NS2 is specifically designed to reduce levels of toxic aldehydes, and is the first therapy to be directed at the putative cause of SLS.
Twelve subjects with SLS and moderate to severe ichthyosis were randomized equally to receive NS2 1.0% dermatologic formulation or vehicle formulation administered once-daily (QD) on a 4 x 10 inch area of skin for two months. Investigators and subjects were blinded to treatment group. Ichthyosis was graded by a blinded central review of digital photographs, as well as by clinical exam, using the Ichthyosis Severity Score, which is comprised of assessments of global impression, scaling, erythema (redness), lichenification (thickness) and excoriation (abrasion). In addition, dermal tissue from subjects was analyzed for biomarkers relevant to fatty aldehyde dehydrogenase deficiency.
NS2 consistently produced clinically meaningful effects in reducing the severity of ichthyosis. As assessed by central review, five of six subjects (83%) treated with NS2 achieved a rating of "almost clear" or "mild" on global assessment. Six of six (100%) subjects treated with NS2 improved over the course of therapy as assessed by central review, and the improvement was greater than that observed with vehicle-treated patients (p < 0.05). For NS2-treated subjects, mean reductions in ichthyosis severity were greater after 8 weeks of therapy than after 4 weeks of therapy, suggesting a disease modifying effect of NS2. Consistent with the clinical activity of NS2, significant dermal biomarker changes were noted in NS2-treated patients but not vehicle-treated patients (p < 0.004). Cholesterol, which is significantly elevated in the skin of SLS patients, was reduced in NS2-treated patients more than in vehicle-treated patients (p < 0.001). NS2 was observed to be generally well tolerated and there were no significant adverse events, serious adverse events or discontinuations in the trial.
"We are thrilled to report positive data from this rigorous and controlled clinical trial studying the use of topical dermatologic NS2 to treat the severe skin disease associated with SLS," said Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "There is currently no FDA-approved therapy for SLS, and we believe these results represent a major milestone for patients afflicted with this disease."
Conference Call and Webcast Information
The Company will hold a conference call on Tuesday, August 9, 2016 at 8:00 a.m. EDT to discuss the results of the clinical trial. The dial-in numbers are 1-888-296-4215 for domestic callers and 1-719-325-2480 for international callers. The conference ID number for both is 4144869. A live webcast of the conference call and accompanying slides will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com.
After the live webcast, the call will remain archived on the Aldeyra Therapeutics website for one year. In addition, a telephonic replay of the call will be available until August 8, 2017. The replay dial-in numbers are 1-888-203-1112 for domestic callers and 1-719-457-0820 for international callers. Please use event passcode 4144869.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, NS2, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. NS2 has not been approved for sale in the U.S. or elsewhere.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck (MRK) Announces KEYTRUDA Phase 3 KEYNOTE-045 Met Primary Endpoint; Trial Stopped Early
- Amgen (AMGN) Announces XGEVA vs. Zoledronic Acid Study Met Primary Endpoint; Secondary Endpoints Missed
- Midstates Petroleum (MPO) Completes Ch. 11 Bankruptcy; Will Trade Under 'MPO'
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!